Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5801416 | 0.81 | PDE4D (0.69) | PDE4DPDE4BMAPTKDM4ENPC1 | |
| SCHEMBL30583450 | 0.77 | PDE4D (1.00) | PDE4DPDE4BNPC1RAB9AAR | |
| SCHEMBL2201643 | 0.77 | PDE4D (1.00) | PDE4DPDE4BNPC1RAB9AAR | |
| SCHEMBL13920723 | 0.76 | MAPT (0.49) | MAPTKDM4ENPC1RAB9AAR | |
| SCHEMBL123446 | 0.76 | PDE4D (0.67) | PDE4DPDE4BMAPTKDM4ENPC1 | |
| SCHEMBL6070168 | 0.74 | PDE4B (0.67) | PDE4DPDE4BMAPTKDM4ENPC1 | |
| SCHEMBL9369901 | 0.74 | MAPT (0.53) | MAPTKDM4ENPC1RAB9AAR | |
| SCHEMBL6070326 | 0.74 | PKM (0.62) | PDE4DPDE4BMAPTKDM4ENPC1 | |
| SCHEMBL3313819 | 0.73 | MAPT (0.60) | MAPTKDM4ENPC1RAB9AAR | |
| SCHEMBL3269737 | 0.73 | PDE4D (0.56) | PDE4DPDE4BMAPTKDM4ESLC34A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-12-25 | — | — | US | claimed |
| US-7087634-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-12-25 | — | — | US | disclosed |
| US-6569885-B1 | Such as 1-(4-bromophenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester; side effect reduction; for treatment of central nervous system disorders | ICOS CORPORATION | 2003-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | PDE4D 5/4885PDE4B 2/4885MAPT 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.